The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Janssen-Cilag (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - Abbvie (Inst); Adaptimmune (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BBB Technologies (Inst); BeiGene (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); Incyte (Inst); Innate Pharma (Inst); Institut de Recherches Internationales Servier (Inst); Janssen Research & Development (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Kirin Pharmaceutical Development (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners (Inst); Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); ose pharma (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); RigonTEC (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NH TherAGuiX (Inst); Pfizer (Inst); Roche (Inst)
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Hossein Borghaei
Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Stéphane Champiat
No Relationships to Disclose
 
Luis G. Paz-Ares
Leadership - Altum Sequencing; European Medicines Agency (I); Genomica
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Sysmex
Research Funding - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech/Abbvie; Geneplus
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; GlaxoSmithKline; Ignyta; Janssen; Jounce Therapeutics; Lilly; Merck Serono; Nektar; Pfizer; Phillips Gilmore Oncology; Roche
 
Michael J. Boyer
Honoraria - AstraZeneca; Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Benitec Biopharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck Sharp & Dohme
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm
 
Hibiki Udagawa
Honoraria - Abbvie; Amco; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie; Amgen; Daiichi Sankyo; MSD
 
Horst-Dieter Hummel
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Janssen-Cilag
 
Ravi Salgia
Consulting or Advisory Role - Abbvie; ARIAD; Iovance Biotherapeutics; Novartis; Octimet
Speakers' Bureau - AstraZeneca; Merck
 
Fiona Helen Blackhall
Consulting or Advisory Role - Abbvie; AstraZeneca; Cell Medica; Ipsen; Medivation; MSD; Regeneron; Roche; Takeda
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Rene J. Boosman
No Relationships to Disclose
 
Wei-Chu Victoria Lai
Consulting or Advisory Role - G1 Therapeutics; PharmaMar
Research Funding - Amgen (Inst); Daiichi Sankyo (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Seagen; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Incuron (Inst); Ipsen (Inst); Loxo (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst)
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals
Honoraria - Abbvie; Amgen; Ascendis Pharma (I); AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Regeneron; Takeda (I)
Consulting or Advisory Role - Abbvie; Amgen; Ascendis Pharma (I); AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Regeneron; Takeda (I)
Research Funding - Abbvie; Bristol-Myers Squibb; Celgene; Novartis
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Regeneron
 
Christine L. Hann
Consulting or Advisory Role - Abbvie; Ascentage Pharma; Bristol-Myers Squibb; Genentech/Roche
Research Funding - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merrimack (Inst)
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Anne C. Chiang
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Genentech/Roche
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Marichu Endraca
Employment - Amgen
 
Neelesh Soman
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Marie-Anne Damiette Smit
Employment - Amgen
Stock and Other Ownership Interests - Amgen